Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina
MWN-AI** Summary
Cardiac Biotech Solutions, Inc. (OTCID: CBSC) announced a significant milestone on September 4, 2025, by signing a five-year exclusive distribution agreement with Noventis Medical. This agreement allows Noventis to distribute CBSC’s innovative non-invasive ambulatory cardiac monitoring products across key Latin American markets, including Costa Rica, Panama, Colombia, and Argentina. The financial commitment from Noventis totals $600,000, reinforcing their partnership.
CEO Charles Martin expressed enthusiasm about this strategic collaboration, highlighting that it enhances CBSC's reach into these important markets and lays the groundwork for potential regional expansion. Notably, the agreement includes a right of first refusal for Noventis regarding future distribution opportunities in other Central and South American countries, allowing for the possibility of furthering their cooperation.
John Quam, President of Noventis Medical, emphasized the critical role of the MyCardia AT product in addressing cardiovascular disease, which remains the leading cause of death in the region. The MyCardia AT technology will provide healthcare professionals with vital early insights into heart issues, enabling better patient care.
CBSC is advancing the global commercialization of its MyCardia AT event monitoring platform, which integrates user-friendly wearable technology with cloud-based services for both iOS and Android users. With regulatory clearance secured in the U.S. and ongoing submissions in Canada and China, this distribution agreement marks an essential step in the company's mission to deliver cutting-edge cardiac monitoring solutions worldwide.
This partnership and product rollout demonstrate CBSC's commitment to innovation and its position as a key player in the rapidly expanding field of ambulatory cardiac monitoring technology. The company plans to keep stakeholders updated with announcements regarding future developments.
MWN-AI** Analysis
Cardiac Biotech Solutions, Inc. (CBSC) has recently made a significant stride by entering into an exclusive five-year distribution agreement with Noventis Medical, covering key Latin American markets: Costa Rica, Panama, Colombia, and Argentina. This strategic partnership, valued at $600,000, is poised to bolster CBSC’s international presence, tapping into a region where cardiovascular diseases are prevalent and represent the leading cause of death. Such a partnership is not just a revenue stream; it positions CBSC to be a crucial player in a region increasingly demanding advanced cardiac monitoring solutions.
Moreover, the agreement includes a right of first refusal for future distribution opportunities, which is a strategic move to secure CBSC’s competitive advantage in the burgeoning Latin American healthcare market. With CBSC’s MyCardia AT event monitoring platform already gaining traction, the collaboration with Noventis enhances its distribution capabilities, allowing the company to leverage localized expertise in these countries.
As CBSC advances its regulatory efforts not only in Latin America but also in Canada and China, this agreement stands as a testament to its potential for further growth. Investors should consider the implications of expanding to emerging markets where the need for non-invasive cardiac monitoring solutions is on the rise.
However, potential investors must also remain cautious. The path to profitability is fraught with challenges typical in emerging markets, including varying regulatory environments and the competitive landscape from both local and international players.
In conclusion, while the recent distribution agreement with Noventis Medical presents a promising growth opportunity for CBSC, it is crucial for potential investors to stay informed on regulatory developments and market conditions that could impact the company’s operational trajectory. Monitoring the execution of the agreement will be key to assessing its long-term value proposition.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAS VEGAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the execution of a new distribution agreement with Noventis Medical, granting the Company five-year exclusive rights to distribute CBSC’s products across Costa Rica, Panama, Colombia, and Argentina.
Under the terms of the agreement, Noventis Medical has committed to a total of $600,000 USD contract value for the distribution rights. In addition, the Company has granted Noventis a right of first refusal for any future distribution opportunities across other Central and South American countries, provided it can match the terms offered by other prospective partners.
“We are delighted to expand our international presence through this new strategic partnership with Noventis Medical,” said Charles Martin, Chief Executive Officer of CBSC. “This agreement strengthens our reach into key Latin American markets and, we believe, provides a solid foundation for additional regional expansion. We also believe that the right of first refusal provision also ensures that our long-term collaboration with Noventis can grow in step with future opportunities across Central and South America.”
John Quam, President of Noventis Medical stated, “Noventis Medical is very excited to collaborate with CBSC and its product, MyCardia AT, to bring a reliable solution for identifying heart issues in the Latin American market. Cardiovascular disease remains the leading cause of death in the region, and this technology provides doctors with early insights so they can address problems and keep patients healthier for longer. We are committed to working alongside the medical community to deliver innovative tools that truly make a difference.”
The Company continues to advance global commercialization of its MyCardia AT event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the U.S. and additional submissions progressing in Canada and China, CBSC’s newest international agreement represents another milestone in its mission to provide state-of-the-art cardiac monitoring solutions worldwide.
As additional new developments occur, Cardiac Biotech Solutions, Inc. will make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About Cardiac Biotech Solutions, Inc.:
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
FAQ**
How does the new distribution agreement between CB Scientific Inc. (CBSC) and Noventis Medical enhance CBSC's competitive position in the Latin American cardiac monitoring market?
What specific market opportunities does CB Scientific Inc. (CBSC) foresee arising from the right of first refusal granted to Noventis Medical for future distribution?
Can CB Scientific Inc. (CBSC) elaborate on the expected impact of its MyCardia AT product on reducing cardiovascular disease prevalence in the countries covered by the new agreement?
How is CB Scientific Inc. (CBSC) planning to leverage its existing regulatory approvals in the U.S., Canada, and China to support its growth in the Latin American markets?
**MWN-AI FAQ is based on asking OpenAI questions about CB Scientific Inc (OTC: CBSC).
NASDAQ: CBSC
CBSC Trading
0.0% G/L:
$0.04 Last:
13,000 Volume:
$0.04 Open:
